These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 432552)

  • 1. Elevated plasma lysozyme in Hodgkin's disease. An indicator of increased macrophage activity?
    Hansen NE; Karle H
    Scand J Haematol; 1979 Feb; 22(2):173-8. PubMed ID: 432552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tissue and plasma lysozyme in Hodgkin's disease.
    Hansen NE; Clausen PP; Karle H; Christoffersen P
    Scand J Haematol; 1981 Sep; 27(3):186-92. PubMed ID: 7313545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Macrophage-histiocyte lysozyme activity in relation to the clinical presentation of Hodgkin's disease. An immunohistochemical study.
    Ree HJ; Crowley JP; Leone LA
    Cancer; 1981 Apr; 47(8):1988-93. PubMed ID: 6164477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutrophil defect in multiple myeloma. Studies on intraneutrophilic lysozyme in multiple myeloma and malignant lymphoma.
    Karle H; Hansen NE; Plesner T
    Scand J Haematol; 1976 Jul; 17(1):62-70. PubMed ID: 959776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monocyte activation in patients with Hodgkin's disease.
    Kávai M; Berényi E; Zsindely A; Szegedi G; Fésüs L
    Int J Cancer; 1984 Oct; 34(4):483-5. PubMed ID: 6149193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum lysozyme activity in patients with Hodgkin's disease undergoing chemotherapy.
    Prokopowicz J; Kemona H; Wysocka J; Kiluk S
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1987; 114(3):338-47. PubMed ID: 2444507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum angiotensin-I-converting enzyme and lysozyme levels in untreated and unsplenectomized patients with Hodgkin's disease.
    Bosi A; Borsotti M; Ghelli P; Tozzi P; Bellesi G; Rossi Ferrini P
    Acta Haematol; 1984; 71(5):329-33. PubMed ID: 6331045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating immune complexes and serum lysozyme levels in untreated Hodgkin's disease. Their relationship to immune function.
    Spinozzi F; Velardi A; Rambotti P; Losito A; Zampi I; Cernetti C; Gerli R; Martelli MF; Grignani F
    J Clin Lab Immunol; 1983 Oct; 12(2):87-92. PubMed ID: 6644793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Two cases of Hodgkin's disease with elevated plasma lysozyme (author's transl)].
    Suda M; Kawabe H; Sasho T; Amagasaki Y; Nishino Y; Iyori S; Mikata A
    Rinsho Ketsueki; 1982 Mar; 23(3):400-7. PubMed ID: 7109236
    [No Abstract]   [Full Text] [Related]  

  • 10. Polymorphonuclear functions in Hodgkin's disease patients at diagnosis, in remission, and in relapse.
    Corberand J; Benchekroun S; Nguyen F; Laharrague P; Pris J
    Cancer Res; 1982 Apr; 42(4):1595-9. PubMed ID: 7060029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phagocytic macrophages in the bone marrow biopsies of children with Hodgkin's disease.
    Penchansky L; Krause JR
    Pediatr Pathol; 1986; 6(4):369-75. PubMed ID: 3588438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunoelectron microscopic study of Hodgkin's disease.
    Mori N; Oka K; Sakuma H; Tsunoda R; Kojima M
    Cancer; 1985 Dec; 56(11):2605-11. PubMed ID: 3902196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tissue culture studies in Hodgkin's disease: Morphologic, cytogenetic, cell surface, and enzymatic properties of cultures derived from splenic tumors.
    Long JC; Zamecnik PC; Aisenberg AC; Atkins L
    J Exp Med; 1977 Jun; 145(6):1484-500. PubMed ID: 68093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NBT test and serum lysozyme activity during remission of Hodgkin's disease.
    Kemona H; Wysocka J; Prokopowicz J; Kiluk S
    Acta Med Pol; 1986; 27(3-4):163-9. PubMed ID: 3445791
    [No Abstract]   [Full Text] [Related]  

  • 15. [Evaluation of the bone marrow granulocyte reserve in patients with Hodgkin's disease during antiblastic polychemo- and radiation therapy].
    Santagati G; Nicolini E; Zibetti G; Paladini G
    Minerva Med; 1978 May; 69(25):1739-43. PubMed ID: 662176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The in vivo effect of thymic factor (thymostimulin) administration on circulating immune complexes and serum lysozyme levels in untreated Hodgkin's disease patients.
    Velardi A; Spinozzi F; Rambotti P; Tabilio A; Losito A; Zampi I; Cernetti C; Martelli MF; Grignani F; Davis S
    J Clin Oncol; 1983 Feb; 1(2):117-25. PubMed ID: 6668495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hodgkin's disease and the non-Hodgkin's lymphomas in childhood.
    Murphy SB; Davis LW
    Semin Oncol; 1974 Mar; 1(1):17-26. PubMed ID: 4220125
    [No Abstract]   [Full Text] [Related]  

  • 18. Phenotypic attributes of the malignant cell population in Hodgkin's disease indicate a monocyte/macrophage origin.
    Olsson L; Behnke O
    Cancer Surv; 1985; 4(2):421-38. PubMed ID: 3842320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Skin window cellularity and macrophage changes in Hodgkin's and non-Hodgkin's lymphomas.
    Sokol RJ; Durrant TE; Hudson G
    Acta Haematol; 1980; 64(4):209-15. PubMed ID: 6781200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Occurrence and patterns of muramidase containing cells in Hodgkin's disease, non-Hodgkin's lymphomas, and reactive hyperplasia.
    Ree HJ; Song JY; Leone LA; Crowley JP; Fanger H
    Hum Pathol; 1981 Jan; 12(1):49-59. PubMed ID: 6162773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.